{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:50:53Z","timestamp":1775616653011,"version":"3.50.1"},"reference-count":42,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]},{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MHC"},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA247771"],"award-info":[{"award-number":["R01 CA247771"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-18-064-01-TBG"],"award-info":[{"award-number":["RSG-18-064-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIA"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,4]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Induction of CD8<jats:sup>+<\/jats:sup> T cells that recognize immunogenic, mutated protein fragments in the context of major histocompatibility class I (MHC-I) is a pressing challenge for cancer vaccine development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the commonly used murine renal adenocarcinoma RENCA cancer model, MHC-I restricted neoepitopes are predicted following next-generation sequencing. Candidate neoepitopes are screened in mice using a potent cancer vaccine adjuvant system that converts short peptides into immunogenic nanoparticles. An identified functional neoepitope vaccine is then tested in various therapeutic experimental tumor settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Conversion of 20 short MHC-I restricted neoepitope candidates into immunogenic nanoparticles results in antitumor responses with multivalent vaccination. Only a single neoepitope candidate, Nesprin-2 L4492R (Nes2LR), induced functional responses but still did so when included within 20-plex or 60-plex particles. Immunization with the short Nes2LR neoepitope with the immunogenic particle-inducing vaccine adjuvant prevented tumor growth at doses multiple orders of magnitude less than with other vaccine adjuvants, which were ineffective. Nes2LR vaccination inhibited or eradicated disease in subcutaneous, experimental lung metastasis and orthotopic tumor models, synergizing with immune checkpoint blockade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings establish the feasibility of using short, MHC-I-restricted neoepitopes for straightforward immunization with multivalent or validated neoepitopes to induce cytotoxic CD8<jats:sup>+<\/jats:sup> T cells. Furthermore, the Nes2LR neoepitope could be useful for preclinical studies involving renal cell carcinoma immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003101","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T11:55:35Z","timestamp":1638532535000},"page":"e003101","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Immunization with short peptide particles reveals a functional CD8<sup>+<\/sup> T-cell neoepitope in a murine renal carcinoma model"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04783311","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xuedan","family":"He","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Dolan","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Computational Research, University at Buffalo, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breandan","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dushyant","family":"Jahagirdar","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chiao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8587-277X","authenticated-orcid":false,"given":"Moriya","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[{"name":"Department of Medicine, State University of New York, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-671X","authenticated-orcid":false,"given":"Fumito","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Ortega","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-4708","authenticated-orcid":false,"given":"Scott I","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-9044","authenticated-orcid":false,"given":"John M L","family":"Ebos","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-884X","authenticated-orcid":false,"given":"Jonathan F","family":"Lovell","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2025100312202209000_9.12.e003101.1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1279"},{"key":"2025100312202209000_9.12.e003101.2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0484-x"},{"key":"2025100312202209000_9.12.e003101.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102908","article-title":"Exploring essential issues for improving therapeutic cancer vaccine trial design","volume":"12","author":"Baxevanis","year":"2020","journal-title":"Cancers"},{"key":"2025100312202209000_9.12.e003101.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.07.010"},{"key":"2025100312202209000_9.12.e003101.5","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.201800060","article-title":"Peptide delivery systems for cancer vaccines","volume":"1","author":"He","year":"2018","journal-title":"Adv Therap"},{"key":"2025100312202209000_9.12.e003101.6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199611\/12)12:6<446::AID-SSU10>3.0.CO;2-T"},{"key":"2025100312202209000_9.12.e003101.7","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318233e5b2"},{"key":"2025100312202209000_9.12.e003101.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h988"},{"key":"2025100312202209000_9.12.e003101.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature08989"},{"key":"2025100312202209000_9.12.e003101.10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100312202209000_9.12.e003101.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3828"},{"key":"2025100312202209000_9.12.e003101.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"2025100312202209000_9.12.e003101.13","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"2025100312202209000_9.12.e003101.14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1561106","article-title":"Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma","volume":"8","author":"Johanns","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100312202209000_9.12.e003101.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0810-y"},{"key":"2025100312202209000_9.12.e003101.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3722"},{"key":"2025100312202209000_9.12.e003101.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001"},{"key":"2025100312202209000_9.12.e003101.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature13988"},{"key":"2025100312202209000_9.12.e003101.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature13387"},{"key":"2025100312202209000_9.12.e003101.20","doi-asserted-by":"publisher","DOI":"10.1038\/nature14426"},{"key":"2025100312202209000_9.12.e003101.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"2025100312202209000_9.12.e003101.22","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1021\/acsnano.0c07680","article-title":"A potent cancer vaccine adjuvant system for particleization of short, synthetic CD8+ T cell epitopes","volume":"15","author":"He","year":"2021","journal-title":"ACS Nano"},{"key":"2025100312202209000_9.12.e003101.23","doi-asserted-by":"crossref","unstructured":"He X , Zhou S , Quinn B . HPV\u2010Associated tumor eradication by vaccination with synthetic short peptides and Particle\u2010Forming liposomes. Small 2021;2007165.","DOI":"10.1002\/smll.202007165"},{"key":"2025100312202209000_9.12.e003101.24","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.2236"},{"key":"2025100312202209000_9.12.e003101.25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv639"},{"key":"2025100312202209000_9.12.e003101.26","doi-asserted-by":"publisher","DOI":"10.1110\/ps.0239403"},{"key":"2025100312202209000_9.12.e003101.27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41565-018-0271-3","article-title":"A malaria vaccine adjuvant based on recombinant antigen binding to liposomes","volume":"13","author":"Huang","year":"2018","journal-title":"Nat Nanotechnol"},{"key":"2025100312202209000_9.12.e003101.28","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201403989"},{"key":"2025100312202209000_9.12.e003101.29","article-title":"Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy","volume":"51485","author":"Tracz","year":"2014","journal-title":"J Vis Exp"},{"key":"2025100312202209000_9.12.e003101.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.01.021"},{"key":"2025100312202209000_9.12.e003101.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1389"},{"key":"2025100312202209000_9.12.e003101.32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11388"},{"key":"2025100312202209000_9.12.e003101.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1003-3"},{"key":"2025100312202209000_9.12.e003101.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7111"},{"key":"2025100312202209000_9.12.e003101.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1656-x"},{"key":"2025100312202209000_9.12.e003101.36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142361"},{"key":"2025100312202209000_9.12.e003101.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1546"},{"key":"2025100312202209000_9.12.e003101.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0175-8"},{"key":"2025100312202209000_9.12.e003101.39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.vaccine.2019.10.073","article-title":"Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes","volume":"38","author":"Federizon","year":"2020","journal-title":"Vaccine"},{"key":"2025100312202209000_9.12.e003101.40","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202005637","article-title":"SARS\u2010CoV\u20102 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv Mater"},{"key":"2025100312202209000_9.12.e003101.41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0930-x"},{"key":"2025100312202209000_9.12.e003101.42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat Mater"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:20:32Z","timestamp":1759519232000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jitc-2021-003101"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003101","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}